Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report
Clinical, Cosmetic and Investigational Dermatology · 2025-09 · Volume 18 · 2133-2139
DOI: 10.2147/ccid.s541725 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2025-09. Verfasst von Jingqiu Fu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
With the widespread long-term use of biologics in plaque psoriasis, reports of paradoxical eczema caused by interleukin-17A (IL-17A) monoclonal antibodies are increasing. This paradoxical eczema (PE) can occasionally require termination of biologic treatment, which may result in suboptimal management of psoriasis and increased risk of disease flare-ups. In the context of PE, therapeutic strategies should prioritize agents with dual efficacy against both the primary inflammatory process and paradoxical dermatitis, such as Janus kinase (JAK) inhibitors, which modulate key cytokine pathways implicated in both conditions. This report describes a novel case of ixekizumab (IXE)-induced paradoxical eczema that was effectively managed using a sequential JAK inhibitor strategy: initial intervention with abrocitinib (100 mg daily for 2 weeks) achieved significant symptom control, followed by 90% lesion clearance after transitioning to upadacitinib (15 mg daily). Throughout the 4 weeks therapeutic course, no tuberculosis reactivation was observed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China.
- Department of Dermatology, Affiliated Dermatology Hospital of Hainan Medical University, Haikou, Hainan, People's Republic of China.
Zitieren
APA
Fu, J., Lu, J., Wu, W., & Wang, P. (2025). Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report. Clinical, Cosmetic and Investigational Dermatology, Volume 18, 2133-2139. https://doi.org/10.2147/ccid.s541725
Vancouver
Fu J, Lu J, Wu W, Wang P. Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report. Clinical, Cosmetic and Investigational Dermatology. 2025;Volume 18:2133-2139. doi:10.2147/ccid.s541725
BibTeX
@article{Fu2025,
author = {Fu, Jingqiu and Lu, Jiejie and Wu, Weiwei and Wang, Ping},
title = {Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2025},
volume = {Volume 18},
pages = {2133--2139},
doi = {10.2147/ccid.s541725}
}
EUVIMED